Page last updated: 2024-11-05

thalidomide and Burkitt Lymphoma

thalidomide has been researched along with Burkitt Lymphoma in 3 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.

Research Excerpts

ExcerptRelevanceReference
"Thalidomide has recently been shown to be useful in the treatment of multiple myeloma and may also be useful in the treatment of other hematological malignancies."3.71S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. ( Anderson, KC; Birsner, AE; D'Amato, RJ; LeBlanc, R; Lentzsch, S; Rogers, MS; Shah, JH; Treston, AM, 2002)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Grommes, C1
Nayak, L1
Tun, HW1
Batchelor, TT1
Chan, TS1
Khong, PL1
Kwong, YL1
Lentzsch, S1
Rogers, MS1
LeBlanc, R1
Birsner, AE1
Shah, JH1
Treston, AM1
Anderson, KC1
D'Amato, RJ1

Reviews

1 review available for thalidomide and Burkitt Lymphoma

ArticleYear
Introduction of novel agents in the treatment of primary CNS lymphoma.
    Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological;

2019

Other Studies

2 other studies available for thalidomide and Burkitt Lymphoma

ArticleYear
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Annals of hematology, 2016, Volume: 95, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydr

2016
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
    Cancer research, 2002, Apr-15, Volume: 62, Issue:8

    Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Lew

2002